CO2019013254A2 - Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias - Google Patents
Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitariasInfo
- Publication number
- CO2019013254A2 CO2019013254A2 CONC2019/0013254A CO2019013254A CO2019013254A2 CO 2019013254 A2 CO2019013254 A2 CO 2019013254A2 CO 2019013254 A CO2019013254 A CO 2019013254A CO 2019013254 A2 CO2019013254 A2 CO 2019013254A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- treatment
- fused bicyclic
- parasitic diseases
- bicyclic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513211P | 2017-05-31 | 2017-05-31 | |
| US201762581919P | 2017-11-06 | 2017-11-06 | |
| PCT/IB2018/053818 WO2018220531A1 (en) | 2017-05-31 | 2018-05-29 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019013254A2 true CO2019013254A2 (es) | 2020-01-17 |
Family
ID=62749123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0013254A CO2019013254A2 (es) | 2017-05-31 | 2019-11-26 | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11384078B2 (enExample) |
| EP (1) | EP3630771B1 (enExample) |
| JP (1) | JP7187490B2 (enExample) |
| KR (1) | KR20200010275A (enExample) |
| CN (1) | CN110678468B (enExample) |
| AR (1) | AR111826A1 (enExample) |
| AU (1) | AU2018276190B2 (enExample) |
| BR (1) | BR112019024804A2 (enExample) |
| CA (1) | CA3060990A1 (enExample) |
| CL (1) | CL2019003467A1 (enExample) |
| CO (1) | CO2019013254A2 (enExample) |
| CR (1) | CR20190545A (enExample) |
| CU (1) | CU24543B1 (enExample) |
| DO (1) | DOP2019000299A (enExample) |
| EC (1) | ECSP19084722A (enExample) |
| ES (1) | ES2927207T3 (enExample) |
| IL (1) | IL270927B (enExample) |
| JO (1) | JOP20190278A1 (enExample) |
| MA (1) | MA50495A (enExample) |
| MX (1) | MX389106B (enExample) |
| PE (1) | PE20201148A1 (enExample) |
| PH (1) | PH12019502652A1 (enExample) |
| RU (1) | RU2738647C1 (enExample) |
| TW (1) | TW201902894A (enExample) |
| UY (1) | UY37745A (enExample) |
| WO (1) | WO2018220531A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
| EP4136066A1 (en) * | 2020-04-17 | 2023-02-22 | DSM IP Assets B.V. | A process for preparation of substituted enamine compounds |
| CN113831320B (zh) * | 2020-06-23 | 2024-04-05 | 上海美悦生物科技发展有限公司 | 一种稠和吡唑类化合物的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10053275A1 (de) * | 2000-10-27 | 2002-05-02 | Dresden Arzneimittel | Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
| WO2012116246A2 (en) | 2011-02-25 | 2012-08-30 | Dow Agrosciences Llc | Pesticidal compostions and processes related thereto |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| LT2925757T (lt) | 2012-11-19 | 2017-12-27 | Novartis Ag | Junginiai ir kompozicijos, skirti parazitinių ligų gydymui |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| JP6392352B2 (ja) * | 2013-12-19 | 2018-09-19 | ノバルティス アーゲー | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
| ES2700352T3 (es) | 2014-12-02 | 2019-02-15 | Bayer Cropscience Ag | Compuestos bicíclicos como pesticidas |
| CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| AR104749A1 (es) * | 2015-05-29 | 2017-08-09 | Glaxosmithkline Ip Dev Ltd | Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento |
| ES2856899T3 (es) * | 2015-08-07 | 2021-09-28 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| CU24516B1 (es) | 2016-05-03 | 2021-05-12 | Bayer Pharma AG | Derivados aromáticos de sulfonamida útiles como medicamentos contra enfermedades asociadas con dolor |
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
-
2017
- 2017-06-16 JO JOP/2019/0278A patent/JOP20190278A1/ar unknown
-
2018
- 2018-05-23 UY UY0001037745A patent/UY37745A/es not_active Application Discontinuation
- 2018-05-24 AR ARP180101377A patent/AR111826A1/es unknown
- 2018-05-29 JP JP2019565535A patent/JP7187490B2/ja not_active Expired - Fee Related
- 2018-05-29 CA CA3060990A patent/CA3060990A1/en active Pending
- 2018-05-29 CU CU2019000095A patent/CU24543B1/es unknown
- 2018-05-29 ES ES18734297T patent/ES2927207T3/es active Active
- 2018-05-29 AU AU2018276190A patent/AU2018276190B2/en not_active Ceased
- 2018-05-29 CR CR20190545A patent/CR20190545A/es unknown
- 2018-05-29 PE PE2019002477A patent/PE20201148A1/es unknown
- 2018-05-29 CN CN201880034658.0A patent/CN110678468B/zh not_active Expired - Fee Related
- 2018-05-29 RU RU2019138326A patent/RU2738647C1/ru active
- 2018-05-29 MA MA050495A patent/MA50495A/fr unknown
- 2018-05-29 WO PCT/IB2018/053818 patent/WO2018220531A1/en not_active Ceased
- 2018-05-29 EP EP18734297.7A patent/EP3630771B1/en active Active
- 2018-05-29 KR KR1020197034689A patent/KR20200010275A/ko not_active Withdrawn
- 2018-05-29 BR BR112019024804A patent/BR112019024804A2/pt not_active Application Discontinuation
- 2018-05-29 MX MX2019014321A patent/MX389106B/es unknown
- 2018-05-29 US US16/615,749 patent/US11384078B2/en not_active Expired - Fee Related
- 2018-05-29 TW TW107118305A patent/TW201902894A/zh unknown
-
2019
- 2019-11-25 PH PH12019502652A patent/PH12019502652A1/en unknown
- 2019-11-26 IL IL270927A patent/IL270927B/en unknown
- 2019-11-26 CO CONC2019/0013254A patent/CO2019013254A2/es unknown
- 2019-11-27 DO DO2019000299A patent/DOP2019000299A/es unknown
- 2019-11-27 CL CL2019003467A patent/CL2019003467A1/es unknown
- 2019-11-27 EC ECSENADI201984722A patent/ECSP19084722A/es unknown
-
2022
- 2022-05-13 US US17/744,432 patent/US20220324863A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CL2020000251A1 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico. | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний | |
| EA201991932A1 (ru) | Производное азитидина | |
| EA202091668A3 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |